Hester Biosciences reported strong Q2 FY27 results with a standalone profit of INR 166.60 million, a 131% increase YoY. Consolidated earnings received a one-time boost of INR 857.68 million from a debt restructuring at its African subsidiary. The company also completed the divestment of its remaining stake in Texas Lifescience Private Limited and approved a USD 1 million loan to support its African operations.
Hester Biosciences Reports Strong Q2 FY27 Performance
Standalone Q2 Profit After Tax hit INR 166.60 million, while Revenue reached INR 829.28 million.
Reader Takeaway: Strong growth in core animal health divisions is bolstered by a significant one-time debt-related gain.
What just happened
Hester Biosciences has announced its financial results for the quarter ended 30 September 2026. The company saw a standalone profit surge of 131% to INR 166.60 million, supported by a 28% increase in revenue. On a consolidated basis, the firm recorded a notable exceptional gain of INR 857.68 million, stemming from a major debt modification at Hester Biosciences Africa Limited, where principal and interest obligations were significantly reduced.
Why this matters
The robust standalone growth reflects strong operational momentum, particularly in the Poultry Healthcare Division, which grew 27% in Q2. The full divestment of the remaining 11% stake in Texas Lifescience Private Limited signals a strategic pivot toward streamlining core operations. Furthermore, the debt restructuring in the African subsidiary improves the consolidated balance sheet profile significantly.
The backstory
Hester Biosciences has been focused on scaling its animal healthcare footprint while simultaneously managing debt levels. The recent financial quarter marks a period of consolidation, where the company exited non-core investments and optimized capital structures across its international subsidiaries to focus on high-margin product growth and market penetration.
What changes now
The Board has approved an unsecured loan of USD 1 million to Hester Biosciences Africa Limited at a 9% interest rate to support working capital. Management remains committed to new product launches and regulatory approvals for the remainder of FY27, aiming to maintain the current growth trajectory in animal health.
Risks to watch
While the standalone performance is positive, investors should monitor the sustainability of growth in the Animal Healthcare division, which saw a decline in the first half of the year before recovering in Q2. Additionally, reliance on subsidiary performance and international market dynamics remains a factor to watch.
Context metrics (time-bound)
- Poultry Healthcare Division revenue grew 27% in Q2 and 37% in H1.
- Standalone EPS for Q2 FY27 stood at INR 19.59, compared to INR 8.48 in Q2 FY26.
What to track next
Watch for updates on new product introductions and progress in market penetration efforts across both the Poultry and Animal Healthcare divisions, as these remain the primary drivers for FY27 profitability.